Xuan Gu Bao·2025-07-04 08:50Market Overview - The market experienced fluctuations with mixed results across the three major indices, with the Shanghai Composite Index approaching the 3500-point mark [1] - Bank stocks continued to perform strongly, with over ten stocks including CITIC Bank, Shanghai Pudong Development Bank, and Industrial Bank reaching historical highs [1] - The electricity sector saw significant gains, with stocks like Huayin Power, Shaoneng Co., and Shenzhen Nanshan Electric A hitting the daily limit [1] - Stablecoin concepts remained active, with stocks such as Jingbeifang, Xinyada, and Jinyi Culture also reaching the daily limit [1] - In contrast, solid-state battery concept stocks collectively adjusted, with Xinyu falling over 10% [1] - Overall, more than 4100 stocks in the Shanghai and Shenzhen markets declined, with a total trading volume of 1.45 trillion [1] Hot Topics RWA Concept - The RWA concept saw a significant rise, with Jinyi Culture achieving two consecutive limit-ups, and stocks like Hopu Co. and Hangzhou Garden also hitting the limit [4] - According to reports, some public funds' Hong Kong subsidiaries are actively preparing for stablecoin sandbox testing, which includes key aspects such as issuance, payment, and asset connection [4] - Huaxia Fund (Hong Kong) is involved in this initiative, indicating a growing interest in virtual asset-related products [4][6] Electricity Sector - The electricity sector experienced a notable surge, with Huayin Power achieving three limit-ups in four days, and stocks like Shaoneng Co. and Shenzhen Nanshan Electric A also hitting the limit [7] - Reports indicate that a significant heatwave is expected, with temperatures in many regions reaching historical highs, which is likely to increase electricity demand [7] - Huayin Power announced an expected net profit increase of 175 to 215 million yuan for the first half of the year [7] Pharmaceutical Sector - The pharmaceutical sector remained active, with stocks like Saili Medical achieving four consecutive limit-ups, and others like Weixin Kang and Guangsheng Tang also performing well [9] - Global breakthrough clinical data is driving activity in overseas licensing markets, with research results accelerating [9] - The introduction of the first Class B medical insurance directory is expected to further expand the innovative drug market, supported by new policy measures [9]